SWX:NOVNPharmaceuticals
Novartis Actinium Deal Backs Radioligand Growth And Valuation Upside Narrative
Novartis (SWX:NOVN) has signed a new long term supply agreement with Niowave Inc. for Actinium 225, an isotope used in radioligand cancer therapies.
The deal is aimed at supporting Novartis's expanding oncology portfolio and addressing the global shortage of Actinium 225.
Niowave plans to increase production capacity to meet Novartis's needs under the agreement.
For investors tracking Novartis at a current share price of CHF123.8, this move ties directly into the company’s focus on oncology...